Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

Contrary to a single-hub model, modern radiopharmaceutical supply chains require a decentralized network of regional manufacturing sites. This approach ensures reliability for time-sensitive isotopes by mitigating risks like weather or transport delays, prioritizing same-day ground delivery over less dependable overnight air.

Relying on a traditional supply chain means inheriting its slow pace, costs, and outdated technology. By bringing core manufacturing in-house, Tesla controls its innovation speed, allowing it to move much faster and develop more integrated products than its competitors.

A key operational challenge in radiopharmaceutical development is the need for a reliable supply of radionuclides for fresh, just-in-time labeling before dosing. This contrasts sharply with conventional drugs that can be manufactured in bulk and stored, adding significant logistical complexity.

When leading beverage manufacturers refused to produce their unique, raw-ingredient recipe, the founders built their own bespoke manufacturing facility. This vertical integration was necessary to maintain product quality and bring their vision to market, despite the challenge of building two businesses at once.

Instead of viewing a pilot plant as just an R&D cost center, design it to be profitable. This self-sustaining model provides commercial validation and helps secure pre-sale agreements, which can then be leveraged to finance a full-scale industrial facility with less investor risk.

Novartis's radioligand drugs have a radioactive half-life requiring delivery from factory to patient within 4-5 days. Building and mastering a global supply chain to handle this extreme logistical complexity at 99.9% on-time delivery creates a significant competitive advantage that is difficult for others to replicate.

For hard tech startups, the decision to vertically integrate and build a factory shouldn't be automatic. It's a strategic imperative only when "cadence"—the speed of iteration and delivery—is the primary competitive advantage. In such cases, the in-house capability to move fast outweighs the high capital cost.

For early-stage hard tech startups, the decision to vertically integrate isn't about margin improvement. It's a question of survival. You should only take on the immense risk and capital intensity of vertical integration if the company literally cannot exist without controlling that part of the supply chain or tech stack.